Chemours (Wilmington, Delaware) reports a net loss of $230 million in the fourth quarter of 2016. The figure, which includes a perfluorooctanoic acid (PFOA) settlement charge of $335 million and other one-time charges totaling $24 million, compares with the loss of $86 million in the year-ago period. Sales totaled $1.3 billion, down 2.8 year over year (YOY). Adjusted earnings of $0.08/share versus $0.01/share in the year-ago period. Adjusted EBITDA for the quarter totaled $239 million, up 81 YOY on improved average prices in titanium technologies, increased Opteon adoption, and cost reductions, says the company.
展开▼
